AIDX
20/20 Biolabs, Inc.
Price Chart
Latest Quote
$0.23
-0.00 (-0.22%)
Current Price
| Previous Close | $0.23 |
| Open | $0.23 |
| Day High | $0.23 |
| Day Low | $0.23 |
| Volume | 128,022 |
Stock Information
| Shares Outstanding | 12.77M |
| Total Debt | $572K |
| Cash Equivalents | $4.55M |
| Revenue | $2.04M |
| Net Income | $-7.12M |
| Sector | Healthcare |
| Industry | Medical Devices |
| Market Cap | $2.96M |
| EPS (TTM) | $-0.75 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $523K |
| Sales | $2.04M |
| Income | $-7.12M |
| Book/sh | $0.13 |
| Cash/sh | $0.36 |
| Employees | 4 |
Financial Ratios
| Quick Ratio | 1.90 |
| Current Ratio | 1.99 |
| Debt/Eq | 18.12 |
Returns & Margins
| ROA | -62.37% |
| ROE | -331.22% |
| Gross Margin | 31.52% |
| Operating Margin | -170.31% |
| Profit Margin | -285.00% |
Ownership
| Insider Ownership | 15.56% |
| Institutional Ownership | 4.04% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/S | 1.45 |
| P/B | 1.75 |
Analyst Data
| Recommendation | none |
| Target Price | $5.00 |
Technical Indicators
| SMA20 | $nan |
| SMA50 | $nan |
| RSI | 23.81 |
| ATR | nan |
| Shares Float | 10.84M |
| Short Float | 0.42% |
| Short Ratio | 0.81 |
| Rel Volume | 1.26 |
Performance History
| Week | nan% |
| Month | nan% |
| Quarter | nan% |
| 6 Months | nan% |
| YTD | nan% |
| 10 Years | nan% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $nan | 173,972 |
| 2026-10-26 | $0.23 | 24,600 |
| 2026-10-23 | $0.24 | 191,500 |
| 2026-10-22 | $0.25 | 128,900 |
| 2026-10-21 | $0.27 | 19,000 |
| 2026-10-20 | $0.27 | 151,600 |
| 2026-10-19 | $0.26 | 398,900 |
| 2026-10-16 | $0.26 | 188,200 |
| 2026-10-15 | $0.28 | 274,300 |
| 2026-10-14 | $0.31 | 268,400 |
| 2026-10-13 | $0.35 | 81,700 |
| 2026-10-12 | $0.37 | 181,600 |
| 2026-10-09 | $0.38 | 64,500 |
| 2026-10-08 | $0.38 | 186,300 |
| 2026-10-07 | $0.34 | 76,400 |
| 2026-10-06 | $0.35 | 68,900 |
| 2026-10-05 | $0.35 | 117,100 |
| 2026-10-02 | $0.38 | 65,300 |
| 2026-10-01 | $0.41 | 52,000 |
| 2026-09-30 | $0.44 | 44,200 |
| 2026-09-29 | $0.41 | 103,000 |
| 2026-09-28 | $0.41 | 41,300 |
About 20/20 Biolabs, Inc.
20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was formerly known as 20/20 GeneSystems, Inc. and changed its name to 20/20 Biolabs, Inc. in March 2025. The company was incorporated in 2000 and is based in Gaithersburg, Maryland.
đ° Latest News
No news articles available at the moment. Check back later for updates on AIDX.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenue | |||
| Reconciled Cost Of Revenue | $1,440,592 | $1,392,032 | $1,315,166 |
| Cost Of Revenue | $1,440,592 | $1,392,032 | $1,315,166 |
| Total Revenue | $2,045,133 | $1,752,343 | $1,424,304 |
| Operating Revenue | $2,045,133 | $1,752,343 | $1,424,304 |
| Expenses | |||
| Interest Expense | $156,207 | $12,646 | $27,915 |
| Total Expenses | $5,376,004 | $7,413,400 | $7,785,766 |
| Other Income Expense | $-273,142 | $42,569 | $-211,082 |
| Other Non Operating Income Expenses | $-280,879 | $58,925 | $-2,009 |
| Net Non Operating Interest Income Expense | $-134,808 | $66,821 | $181,235 |
| Interest Expense Non Operating | $156,207 | $12,646 | $27,915 |
| Operating Expense | $3,935,412 | $6,021,368 | $6,470,600 |
| General And Administrative Expense | - | $4,759,587 | $5,061,450 |
| Income & Earnings | |||
| Net Income From Continuing Operation Net Minority Interest | $-3,738,821 | $-5,551,667 | $-6,391,309 |
| Net Interest Income | $-134,808 | $66,821 | $181,235 |
| Interest Income | $21,399 | $79,467 | $209,150 |
| Normalized Income | $-3,746,558 | $-5,535,311 | $-6,182,236 |
| Net Income From Continuing And Discontinued Operation | $-3,738,821 | $-5,551,667 | $-6,391,309 |
| Total Operating Income As Reported | $-3,330,871 | $-5,677,413 | $-6,570,535 |
| Net Income Common Stockholders | $-3,738,821 | $-5,551,667 | $-6,391,309 |
| Net Income | $-3,738,821 | $-5,551,667 | $-6,391,309 |
| Net Income Including Noncontrolling Interests | $-3,738,821 | $-5,551,667 | $-6,391,309 |
| Net Income Continuous Operations | $-3,738,821 | $-5,551,667 | $-6,391,309 |
| Pretax Income | $-3,738,821 | $-5,551,667 | $-6,391,309 |
| Special Income Charges | $0 | $-16,356 | $-209,073 |
| Interest Income Non Operating | $21,399 | $79,467 | $209,150 |
| Operating Income | $-3,330,871 | $-5,661,057 | $-6,361,462 |
| Gross Profit | $604,541 | $360,311 | $109,138 |
| Per Share | |||
| Diluted EPS | $-0.36 | $-0.54 | $-0.62 |
| Basic EPS | $-0.36 | $-0.54 | $-0.62 |
| Other | |||
| Tax Effect Of Unusual Items | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-3,512,375 | $-5,386,908 | $-5,987,028 |
| Total Unusual Items | $7,737 | $-16,356 | $-209,073 |
| Total Unusual Items Excluding Goodwill | $7,737 | $-16,356 | $-209,073 |
| Reconciled Depreciation | $77,976 | $135,757 | $167,293 |
| EBITDA (Bullshit earnings) | $-3,504,638 | $-5,403,264 | $-6,196,101 |
| EBIT | $-3,582,614 | $-5,539,021 | $-6,363,394 |
| Diluted Average Shares | $10,347,232 | $10,347,232 | $10,347,232 |
| Basic Average Shares | $10,347,232 | $10,347,232 | $10,347,232 |
| Diluted NI Availto Com Stockholders | $-3,738,821 | $-5,551,667 | $-6,391,309 |
| Tax Provision | $0 | $0 | $0 |
| Impairment Of Capital Assets | $0 | $16,356 | $209,073 |
| Gain On Sale Of Security | $7,737 | - | - |
| Research And Development | $592,569 | $1,261,781 | $1,409,150 |
| Selling General And Administration | $3,342,843 | $4,759,587 | $5,061,450 |
| Other Gand A | - | $3,208,824 | $4,169,118 |
| Salaries And Wages | - | $1,550,763 | $892,332 |
Fetched: 2026-10-13
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Assets | |||
| Net Tangible Assets | $-492,632 | $1,006,310 | $3,760,963 |
| Total Assets | $4,137,357 | $3,584,408 | $6,367,828 |
| Total Non Current Assets | $2,666,224 | $1,550,183 | $2,067,396 |
| Other Non Current Assets | $23,057 | $161,957 | $64,883 |
| Non Current Deferred Assets | $1,507,794 | $0 | $148,387 |
| Goodwill And Other Intangible Assets | $473,407 | $499,172 | $526,529 |
| Other Intangible Assets | $473,407 | $499,172 | $526,529 |
| Current Assets | $1,471,133 | $2,034,225 | $4,300,432 |
| Other Current Assets | $128,975 | $67,780 | - |
| Inventory | $116,217 | $47,164 | $60,668 |
| Receivables | $199,954 | $135,272 | $68,834 |
| Accounts Receivable | $199,954 | $135,272 | $68,834 |
| Allowance For Doubtful Accounts Receivable | $-81,043 | $-29,346 | $-29,346 |
| Gross Accounts Receivable | $280,997 | $164,618 | $98,180 |
| Cash Cash Equivalents And Short Term Investments | $1,025,987 | $1,784,009 | $4,089,461 |
| Cash And Cash Equivalents | $1,025,987 | $1,784,009 | $4,089,461 |
| Non Current Prepaid Assets | - | $106,430 | $150,000 |
| Prepaid Assets | - | $67,780 | $81,469 |
| Debt | |||
| Total Debt | $1,358,639 | $839,550 | $1,232,501 |
| Long Term Debt And Capital Lease Obligation | $1,108,080 | $673,848 | $1,068,713 |
| Long Term Debt | $619,355 | - | $229,164 |
| Current Debt And Capital Lease Obligation | $250,559 | $165,702 | $163,788 |
| Current Debt | $74,611 | - | - |
| Other Current Borrowings | $74,611 | - | - |
| Liabilities | |||
| Total Liabilities Net Minority Interest | $4,156,582 | $2,078,926 | $2,080,336 |
| Total Non Current Liabilities Net Minority Interest | $1,693,441 | $723,848 | $1,068,713 |
| Derivative Product Liabilities | $543,545 | $0 | - |
| Non Current Deferred Liabilities | $41,816 | $50,000 | $0 |
| Current Liabilities | $2,463,141 | $1,355,078 | $1,011,623 |
| Other Current Liabilities | $143,382 | - | - |
| Current Deferred Liabilities | $414,871 | $470,451 | $254,871 |
| Payables And Accrued Expenses | $1,654,329 | $718,925 | $592,964 |
| Payables | $868,545 | $372,303 | $360,279 |
| Accounts Payable | $868,545 | $372,303 | $360,279 |
| Equity | |||
| Common Stock Equity | $-66,399 | $1,458,700 | $4,241,334 |
| Preferred Stock Equity | $47,174 | $46,782 | $46,158 |
| Total Equity Gross Minority Interest | $-19,225 | $1,505,482 | $4,287,492 |
| Stockholders Equity | $-19,225 | $1,505,482 | $4,287,492 |
| Retained Earnings | $-33,247,219 | $-29,508,398 | $-23,956,731 |
| Other Equity Interest | - | $-28,734 | - |
| Other | |||
| Ordinary Shares Number | $10,347,232 | $10,347,232 | $10,347,232 |
| Share Issued | $10,347,232 | $10,347,232 | $10,347,232 |
| Tangible Book Value | $-539,806 | $959,528 | $3,714,805 |
| Invested Capital | $627,567 | $1,458,700 | $4,470,498 |
| Working Capital | $-992,008 | $679,147 | $3,288,809 |
| Capital Lease Obligations | $664,673 | $839,550 | $1,003,337 |
| Total Capitalization | $600,130 | $1,505,482 | $4,516,656 |
| Additional Paid In Capital | $33,126,398 | $30,947,601 | $28,150,334 |
| Capital Stock | $101,596 | $95,013 | $93,889 |
| Common Stock | $54,422 | $48,231 | $47,731 |
| Preferred Stock | $47,174 | $46,782 | $46,158 |
| Non Current Deferred Revenue | $41,816 | $50,000 | $0 |
| Long Term Capital Lease Obligation | $488,725 | $673,848 | $839,549 |
| Current Deferred Revenue | $414,871 | $470,451 | $254,871 |
| Current Capital Lease Obligation | $175,948 | $165,702 | $163,788 |
| Current Accrued Expenses | $785,784 | $346,622 | $232,685 |
| Net PPE | $661,966 | $889,054 | $1,177,597 |
| Accumulated Depreciation | $-1,162,220 | $-464,581 | $-477,242 |
| Gross PPE | $1,824,186 | $1,353,635 | $1,654,839 |
| Leases | $12,221 | $12,221 | $12,221 |
| Other Properties | $1,566,460 | $1,095,909 | $1,397,113 |
| Machinery Furniture Equipment | $245,505 | $245,505 | $245,505 |
| Properties | $0 | $0 | $0 |
Fetched: 2026-10-13
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Free Cash Flow | |||
| Free Cash Flow | $-1,919,720 | $-2,598,785 | $-4,523,735 |
| Operating Activities | |||
| Operating Cash Flow | $-1,919,720 | $-2,598,785 | $-4,479,971 |
| Cash Flow From Continuing Operating Activities | $-1,919,720 | $-2,598,785 | $-4,479,971 |
| Operating Gains Losses | $-7,737 | - | - |
| Investing Activities | |||
| Investing Cash Flow | - | $0 | $-43,764 |
| Cash Flow From Continuing Investing Activities | - | $0 | $-43,764 |
| Capital Expenditure | - | - | $-43,764 |
| Financing Activities | |||
| Issuance Of Capital Stock | $197,088 | $293,333 | $0 |
| Financing Cash Flow | $1,161,698 | $293,333 | $-194,379 |
| Cash Flow From Continuing Financing Activities | $1,161,698 | $293,333 | $-194,379 |
| Net Other Financing Charges | $-23,862 | - | $-148,387 |
| Net Preferred Stock Issuance | $192,338 | $293,333 | $0 |
| Preferred Stock Issuance | $192,338 | $293,333 | $0 |
| Net Common Stock Issuance | $4,750 | $0 | - |
| Common Stock Issuance | $4,750 | $0 | - |
| Other | |||
| Issuance Of Debt | $988,472 | $0 | - |
| Interest Paid Supplemental Data | $0 | $0 | $0 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 |
| End Cash Position | $1,025,987 | $1,784,009 | $4,089,461 |
| Beginning Cash Position | $1,784,009 | $4,089,461 | $8,807,575 |
| Changes In Cash | $-758,022 | $-2,305,452 | $-4,718,114 |
| Net Issuance Payments Of Debt | $988,472 | $0 | $-46,575 |
| Net Long Term Debt Issuance | $988,472 | $0 | $-46,575 |
| Long Term Debt Issuance | $988,472 | $0 | - |
| Change In Working Capital | $836,734 | $619,692 | $225,812 |
| Change In Other Working Capital | $-63,765 | $265,580 | $-61,351 |
| Change In Payables And Accrued Expense | $956,528 | $192,044 | $-501,704 |
| Change In Accrued Expense | $460,286 | $180,019 | $-400,400 |
| Change In Interest Payable | $41,023 | $7,667 | $16,710 |
| Change In Payable | $496,242 | $12,025 | $-101,304 |
| Change In Account Payable | $496,242 | $12,025 | $-104,003 |
| Change In Prepaid Assets | $77,705 | $215,002 | $66,371 |
| Change In Inventory | $-69,052 | $13,504 | $26,406 |
| Change In Receivables | $-64,682 | $-66,438 | $696,090 |
| Changes In Account Receivables | $-64,682 | $-66,438 | $696,090 |
| Other Non Cash Items | $280,764 | - | - |
| Stock Based Compensation | $516,180 | $2,176,098 | $1,303,952 |
| Asset Impairment Charge | $0 | $16,356 | $209,073 |
| Amortization Of Securities | $115,184 | $4,979 | $5,208 |
| Depreciation Amortization Depletion | $77,976 | $135,757 | $167,293 |
| Depreciation And Amortization | $77,976 | $135,757 | $167,293 |
| Amortization Cash Flow | $22,500 | $22,500 | $24,786 |
| Amortization Of Intangibles | $22,500 | $22,500 | $24,786 |
| Depreciation | $55,476 | $113,257 | $142,507 |
| Gain Loss On Investment Securities | $-7,737 | - | - |
| Net Income From Continuing Operations | $-3,738,821 | $-5,551,667 | $-6,391,309 |
| Repayment Of Debt | - | $0 | $-46,575 |
| Proceeds From Stock Option Exercised | - | $0 | $583 |
| Long Term Debt Payments | - | $0 | $-46,575 |
| Net Intangibles Purchase And Sale | - | $0 | $-34,381 |
| Purchase Of Intangibles | - | $0 | $-34,381 |
| Net PPE Purchase And Sale | - | $0 | $-9,383 |
| Purchase Of PPE | - | $0 | $-9,383 |
Fetched: 2026-10-13